Literature DB >> 31399984

Renal Interstitial Lymphangiogenesis in Renal Fibrosis.

Gang Xu1.   

Abstract

The basic physiological functions of the lymphatic system include absorption of water and macromolecular substances in the interstitial fluid to maintain the fluid homeostasis, promoting the intestinal absorption of nutrients such as lipids and vitamins from food. Recent studies have found that lymphangiogenesis is associated with some pathological conditions, such as tumor metastasis, injury repair, and chronic inflammation. For a long time, the study of lymphatic vessels (LVs) has been stagnant because of the lack of lymphatic-specific cytology and molecular markers. Renal interstitial lymphangiogenesis is found in patients with chronic kidney disease (CKD) and a series of animal models of renal fibrosis. Intervention of the formation or maturation of LVs in renal tissue of CKD may reduce the drainage of inflammatory cells, attenuate chronic inflammation, delay the progression of renal fibrosis, and improve renal function. This review will summarize the latest findings on renal interstitial lymphangiogenesis in CKD.

Entities:  

Keywords:  Immune responses; Kidney disease; Lymphangiogenesis; Renal fibrosis

Mesh:

Year:  2019        PMID: 31399984     DOI: 10.1007/978-981-13-8871-2_27

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Lymphangiogenesis in renal fibrosis arises from macrophages via VEGF-C/VEGFR3-dependent autophagy and polarization.

Authors:  Ying Zhang; Conghui Zhang; Lixi Li; Xinjun Liang; Peng Cheng; Qing Li; Xiaoyan Chang; Kun Wang; Shuai Huang; Yueqiang Li; Yanyan Liu; Gang Xu
Journal:  Cell Death Dis       Date:  2021-01-21       Impact factor: 8.469

2.  Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis.

Authors:  Ziqian Liu; Cuijuan Zhang; Juan Hao; Gege Chen; Lingjin Liu; Yunzhao Xiong; Yi Chang; Hui Li; Tatsuo Shimosawa; Fan Yang; Qingyou Xu
Journal:  Exp Ther Med       Date:  2022-08-11       Impact factor: 2.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.